SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

NCT03558191 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: SHR-1210

Sponsor

Jiangsu HengRui Medicine Co., Ltd.